Greater Regulatory Scrutiny Could Weigh on Biotech ETFs

Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) and SPDR S&P Biotech ETF (NYSEArca: XBI) both decreased 5.8% while...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.